Big Buttons

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Compounding vs. counterfeit — ABC News gets it

  When ABC News wanted to do a story on compounded GLP-1s, it turned to APC. Of course. read more →

• No no, Novo!

  Novo Nordisk asked the FDA to put semaglutide on the Demonstrably Difficult to Compound (DDC) list, and now APC has formally responded, pulling exactly zero punches. read more →

• About that Diabetes Association statement …

  The American Diabetes Association gets a good portion of its funding from pharmaceutical companies, including Eli Lilly and Novo Nordisk. read more →

• Foundation welcomes 2025 board members

  Congratulations to the newest members of the Pharmacy Compounding Foundation Board of Directors read more →

• End Drug Shortages Act intro’d in Congress

  The legislation would expand the sources the FDA may use to declare drug shortages. read more →

• FDA tirzepatide ‘reconsideration’ period extended

  FDA agreed to extend until December 19 a final report on tirzepatide availability to the court.  read more →

• NPR hits the GLP-1 nail on the head

  A National Public Radio piece this week tackled the issue of compounded GLP-1 drugs and got the facts and nuance just right. read more →

More News

You might have heard that the American Diabetes Association (which we should mention gets a good portion of its funding from pharmaceutical companies, including Eli Lilly and Novo Nordisk) issued a statement recommending against compounded GLP-1 drugs.

The ADA makes several inaccurate and misleading claims about the quality, safety, and role of compounded medications. APC will soon be releasing a statement to address those mischaracterizations and, as always, highlight the critical role compounded therapies have played in ensuring patient access during prolonged shortages of FDA-approved medications.